Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 3,141 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 193,851 shares, the days-to-cover ratio is presently 0.0 days.
Bioxytran Stock Performance
OTCMKTS BIXT remained flat at $0.02 on Thursday. 93,000 shares of the company’s stock were exchanged, compared to its average volume of 80,077. Bioxytran has a 52 week low of $0.02 and a 52 week high of $0.09. The company has a market capitalization of $2.64 million, a PE ratio of -0.77 and a beta of 2.32. The business has a fifty day moving average price of $0.02 and a 200 day moving average price of $0.03.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.01) earnings per share (EPS) for the quarter.
About Bioxytran
BioXyTran, Inc is a biotechnology company focused on developing nanotechnology-based therapeutic products. Its research has centered on methods for delivering oxygen and other therapeutic agents through the bloodstream, with the goal of addressing conditions associated with inadequate blood flow and oxygen deprivation.
The company’s lead development program has been identified as BXT-25, an oxygen-delivery product intended for potential use in ischemic conditions, including acute ischemic stroke.
See Also
- Five stocks we like better than Bioxytran
- Synopsys Signals Confidence With $1B Accelerated Buyback, Analysts Raise Targets
- Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But Up
- Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?
- Failed Breakout in Tech? 3 Sectors Leading the Market Rotation
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
